SMFM关于足月低危初产妇选择性引产的声明:ARRIVE试验
本文回顾了ARRIVE随机对照试验,该试验于2014年3月至2017年8月由尤尼斯·肯尼迪·施莱弗国家儿童健康与人类发展研究所母胎医学单位网络开展,旨在检验低危初产妇39周选择性引产与期待治疗相比能否降低围产期死亡或严重新生儿发病率复合结局风险。本文旨在为研究结果的实施提供指导。
要点
- ARRIVE试验为多中心、非盲随机对照试验,纳入孕周可靠且无产科或内科并发症的初产妇。
- 试验假设为39周选择性引产较期待治疗降低围产期死亡或严重新生儿发病率复合结局风险。
- 本声明基于ARRIVE试验结果,为临床实施提供指导。
核心结论
- 本文回顾ARRIVE试验发现,并为研究结果的实施提供指导。
研究设计与样本
- ARRIVE试验为多中心、非盲随机对照试验,由尤尼斯·肯尼迪·施莱弗国家儿童健康与人类发展研究所母胎医学单位网络于2014年3月至2017年8月开展,纳入孕周可靠且无产科或内科并发症的初产妇,不论宫颈检查是否有利。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A Randomized Trial of Induction Versus Expectant Management (ARRIVE) was conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network from March 2014 to August 2017.This large multicenter, unmasked, randomized controlled trial was performed to test the hypothesis that elective IOL at 39 weeks of gestation, compared with expectant management among low-risk nulliparous women, reduces the risk of a composite outcome of perinatal death or severe neonatal morbidity. Nulliparous women with reliable dating and no obstetric or medical complications were eligible, regardless of favorability of cervical examination. The purpose of this document is to review the findings of the recent randomized trial and to provide guidance for implementation of the study findings.
引用
- SMFM Statement on Elective Induction of Labor in Low-Risk Nulliparous Women at Term: the ARRIVE Trial. Am J Obstet Gynecol. 2018. PMID: 30098985. doi:10.1016/j.ajog.2018.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。